The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a si...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-01-01
|
| Series: | Leukemia Research Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048918300499 |
| _version_ | 1818022205192142848 |
|---|---|
| author | Grace Xiuqing Li Lan Wang Bassam Yaghmour Giridharan Ramsingh George Yaghmour |
| author_facet | Grace Xiuqing Li Lan Wang Bassam Yaghmour Giridharan Ramsingh George Yaghmour |
| author_sort | Grace Xiuqing Li |
| collection | DOAJ |
| description | Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting. Keywords: Acute myeloid leukemia, FLT3, Hematopoietic stem cell transplant, Tyrosine kinase inhibitors, Multikinase inhibitors, Drug resistance |
| first_indexed | 2024-04-14T08:29:19Z |
| format | Article |
| id | doaj.art-ba22df9f83214e6e86938214499c15f3 |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-04-14T08:29:19Z |
| publishDate | 2018-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-ba22df9f83214e6e86938214499c15f32022-12-22T02:03:58ZengElsevierLeukemia Research Reports2213-04892018-01-01102636The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplantGrace Xiuqing Li0Lan Wang1Bassam Yaghmour2Giridharan Ramsingh3George Yaghmour4Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Keck School of Medicine of USC, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United StatesDepartment of Medicine, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA 90033, United StatesDepartment of Pulmonary and Critical Care, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA 90033, United StatesJane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Keck School of Medicine of USC, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United StatesJane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Keck School of Medicine of USC, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States; Corresponding author.Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting. Keywords: Acute myeloid leukemia, FLT3, Hematopoietic stem cell transplant, Tyrosine kinase inhibitors, Multikinase inhibitors, Drug resistancehttp://www.sciencedirect.com/science/article/pii/S2213048918300499 |
| spellingShingle | Grace Xiuqing Li Lan Wang Bassam Yaghmour Giridharan Ramsingh George Yaghmour The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant Leukemia Research Reports |
| title | The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| title_full | The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| title_fullStr | The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| title_full_unstemmed | The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| title_short | The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| title_sort | role of flt3 inhibitors as maintenance therapy following hematopoietic stem cell transplant |
| url | http://www.sciencedirect.com/science/article/pii/S2213048918300499 |
| work_keys_str_mv | AT gracexiuqingli theroleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT lanwang theroleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT bassamyaghmour theroleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT giridharanramsingh theroleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT georgeyaghmour theroleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT gracexiuqingli roleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT lanwang roleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT bassamyaghmour roleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT giridharanramsingh roleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant AT georgeyaghmour roleofflt3inhibitorsasmaintenancetherapyfollowinghematopoieticstemcelltransplant |